CMPS:NASDAQ
Compass Pathways PLC
$11.90
arrow_downward
-0.42%(-0.050) 1D
$11.98
arrow_upward
+0.65% (+0.078)bedtimeAfter hours
Closed: Oct 2, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CMPS...
Open
$12.00
High
$12.07
Low
$11.63
Mkt. cap
1.65B
Avg. vol.
2.69M
Volume
2.66M
52-wk high
$15.87
52-wk low
$4.88
EPS
-$3.47
Beta
2.55
Shares outstanding
138.48M
No. of employees
156
Open
$12.00
High
$12.07
Low
$11.63
Mkt. cap
1.65B
Avg. vol.
2.69M
Volume
2.66M
52-wk high
$15.87
52-wk low
$4.88
EPS
-$3.47
Beta
2.55
Shares outstanding
138.48M
No. of employees
156
News stories
From web sources and news partners
AD HOC NEWS
·
4 hours ago
COMPASS Pathways stock gets new employee grants on Nasdaq
Profile
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin, has completed phase 3 clinical trials for treatment-resistant depression. The results showed clear benefit to participants as measured on the MADRS depression rating scale. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration. It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine.
Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder New Drug Application, Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus. Wikipedia
About Compass Pathways PLC